Amryt submits a new drug application to the us food and drug administration for oleogel-s10* (filsuvez®)

Dublin, ireland, and boston ma, march 31, 2021, amryt (nasdaq: amyt, aim: amyt), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces the completion of the rolling submission of a new drug application (“nda”) to the u.s. food and drugs administration (“fda”) for oleogel-s10 for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa (“eb”).  eb is a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment.
AMYT Ratings Summary
AMYT Quant Ranking